Earnings Call · Q1 FY2026·2026-05-15

Q1 26EPS -15.09%·Rev n/aQ4 25EPS +1.08%·Rev n/aQ3 25EPS -6.12%·Rev n/aQ2 25EPS +9.80%·Rev n/a⚠ consensus missing

ARS Pharmaceuticals, Inc. SPRY

Justin Chakma — Chief Business Officer

Richard Lowenthal — PRESIDENT AND CEO

Eric Karas — Chief Commercial Officer

Kathleen Scott — Chief Financial Officer

−6.5%1d on move date−5.3% vs SPY3d−9.7%5d+3.7%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SPRY calls or request research access.

More SPRY calls Browse calls Request research access